Last reviewed · How we verify
Ticagrelor first
Ticagrelor is a direct-acting P2Y12 receptor antagonist that inhibits platelet aggregation by blocking adenosine diphosphate (ADP) signaling.
Ticagrelor is a direct-acting P2Y12 receptor antagonist that inhibits platelet aggregation by blocking adenosine diphosphate (ADP) signaling. Used for Acute coronary syndrome (ACS) for reduction of cardiovascular death, myocardial infarction, and stent thrombosis, Chronic coronary disease for secondary prevention of cardiovascular events.
At a glance
| Generic name | Ticagrelor first |
|---|---|
| Also known as | T-C |
| Sponsor | Ping-Yen Liu |
| Drug class | P2Y12 receptor antagonist |
| Target | P2Y12 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ticagrelor binds reversibly to the P2Y12 receptor on platelet surfaces, preventing ADP-mediated platelet activation and aggregation. This reduces thrombotic events in patients with acute coronary syndrome or a history of myocardial infarction. Unlike prodrug thienopyridines, ticagrelor is active without hepatic metabolism.
Approved indications
- Acute coronary syndrome (ACS) for reduction of cardiovascular death, myocardial infarction, and stent thrombosis
- Chronic coronary disease for secondary prevention of cardiovascular events
Common side effects
- Bradycardia
- Dyspnea
- Bleeding (major and minor)
- Ventricular pauses
Key clinical trials
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (PHASE4)
- Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE (PHASE3)
- Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea (NA)
- Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA (PHASE3)
- The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin (PHASE4)
- Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA (PHASE3)
- Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ticagrelor first CI brief — competitive landscape report
- Ticagrelor first updates RSS · CI watch RSS
- Ping-Yen Liu portfolio CI